Skip to main content
新芝生物 logo

新芝生物 — Investor Relations & Filings

Ticker · 920685 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 390 across all filing types
Latest filing 2024-01-02 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920685

About 新芝生物

https://www.scientz.com/

Scientz Biotechnology specializes in the design and manufacture of high-performance life science instruments and laboratory equipment. The product range features ultrasonic cell disruptors, freeze dryers, gene guns, and high-pressure homogenizers, which are essential for sample preparation, cell lysis, and genetic engineering. The company also provides specialized solutions for tissue grinding, ultrasonic cleaning, and precise temperature control. These instruments serve a broad spectrum of applications in molecular biology, pharmaceutical research, environmental science, and agricultural technology. By integrating advanced ultrasonic and cryogenic technologies, Scientz supports research institutions and industrial laboratories in achieving accurate and reproducible results across various scientific disciplines.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Ningbo New Gen Bio-tech Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the authorization, types of financial products invested in, amounts, expected yields, risk controls, and internal oversight related to the use of idle raised funds. The document includes references to board and shareholder meeting resolutions approving the cash management plan. It is a regulatory announcement about the company's capital management activities, specifically the use of idle raised funds for cash management, rather than a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly results, nor is it a report publication announcement or certification. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage related to raised funds management.
2024-01-02 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Ningbo Xinzhi Biotechnology Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It includes specifics about authorized cash management, types of financial products invested in, amounts, expected yields, risk controls, and internal oversight. The document references prior board and shareholder meeting approvals and provides detailed tables of current and expired cash management products. It is not a full financial report like an Annual or Interim Report, nor is it a simple announcement of a report publication. It is also not related to earnings, dividends, mergers, or governance changes. The content fits best with a Capital/Financing Update (CAP) as it concerns the management and use of raised capital funds and their investment status. The document length (6902 characters) and detailed financial product data support this classification with high confidence.
2023-12-14 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Ningbo New Gen Bio-tech Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the authorization, types of financial products used, amounts, expected yields, risk controls, and internal oversight related to the use of idle raised funds. The document includes references to board and shareholder meeting approvals but does not contain financial statements or comprehensive financial performance data. It is a regulatory disclosure about capital management activities related to fundraising proceeds, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activities, not just a brief notice or certification, so it is not RNS or RPA.
2023-12-03 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement about the progress of a share repurchase program by Ningbo NewGen Bio-Tech Co., Ltd. It includes specifics on the repurchase plan, purpose, method, price limits, quantities, funding sources, implementation period, and progress as of a certain date. The text focuses on the company's buyback of its own shares and the status of that buyback, including quantities repurchased and prices paid. There is no indication that this is a full financial report, earnings release, or regulatory filing unrelated to share repurchases. The document length is 2088 characters, which is relatively short but contains substantive details about the share repurchase activity itself, not just an announcement of a report publication. Therefore, the document fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-12-03 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Ningbo New Gen Bio-tech Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the authorization, types of financial products invested in, amounts, expected yields, risk controls, and internal oversight related to the use of idle raised funds. The document includes tables of current and expired cash management products and references board and shareholder meeting resolutions approving the use of funds. There is no presentation of full financial statements or comprehensive financial performance data. The document is a regulatory announcement about financing activities related to the use of raised funds, specifically cash management, rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing activities, not just a brief notice or certification, so it is not RNS or RPA. Confidence is high due to clear content focus on cash management of raised funds.
2023-11-21 Chinese
北京炜衡(宁波)律师事务所关于宁波新芝生物科技股份有限公司2023年第三次临时股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter by a law firm on the convening, attendance, and voting procedures and results of Ningbo Xinzhi Biotech’s 2023 third extraordinary general meeting of shareholders. It presents the detailed vote counts for each resolution, verifying that the meeting and voting comply with laws and the company charter. This aligns with the category for official results from shareholder votes at an EGM, which is “Declaration of Voting Results & Voting Rights Announcements” (DVA).
2023-11-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.